NeuroMetrix, Inc. (NURO)
NASDAQ: NURO · Real-Time Price · USD
4.340
+0.430 (11.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
NeuroMetrix Revenue
NeuroMetrix had revenue of $587.31K in the quarter ending September 30, 2024, a decrease of -51.19%. This brings the company's revenue in the last twelve months to $3.77M, down -41.41% year-over-year. In the year 2023, NeuroMetrix had annual revenue of $5.90M, down -28.52%.
Revenue (ttm)
$3.77M
Revenue Growth
-41.41%
P/S Ratio
2.01
Revenue / Employee
$144,914
Employees
26
Market Cap
8.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.90M | -2.35M | -28.52% |
Dec 31, 2022 | 8.26M | 2.58K | 0.03% |
Dec 31, 2021 | 8.25M | 875.52K | 11.87% |
Dec 31, 2020 | 7.38M | -1.89M | -20.43% |
Dec 31, 2019 | 9.27M | -6.82M | -42.37% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
IM Cannabis | 38.04M |
Precipio | 17.41M |
Jaguar Health | 10.48M |
RedHill Biopharma | 3.71M |
Onconetix | 1.46M |
FOXO Technologies | 1.34M |
Soligenix | 364.18K |
Virax Biolabs Group | 156.42K |
NURO News
- 3 months ago - NeuroMetrix Reiterates its Review of Strategic Alternatives - GlobeNewsWire
- 3 months ago - NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call - GlobeNewsWire
- 6 months ago - NeuroMetrix Reports Q1 2024 Business Highlights - GlobeNewsWire
- 7 months ago - NeuroMetrix Announces Steps Taken to Enhance Shareholder Value - GlobeNewsWire
- 9 months ago - NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy - GlobeNewsWire
- 9 months ago - NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia - GlobeNewsWire
- 9 months ago - Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired - Accesswire